Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its anti-idiotype antibodies.
RP215 monoclonal antibody (Mab) was shown to recognize carbohydrate-associated epitope(s) in the heavy chains of cancer cell-expressed immunoglobulins, designated in general as CA215 pan cancer marker. Growth inhibitions of tumor cells in vitro by RP215 Mab and antibodies against its anti-idiotype (anti-id) antibodies were investigated. Polyclonal rabbit anti-id antibodies and the corresponding rat anti-id Mabs were generated and characterized. Following immunizations in mice, antisera raised against anti-id antibodies were analyzed by typical immunoassays. It was observed that mouse anti-anti-id sera (Ab3) revealed binding affinity and specificity to CA215 that are comparable to those of RP215. Both RP215 and Ab3 were shown to induce apoptosis of cultured cancer cells in vitro by TUNEL and MTT assays. These experimental observations were consistent with that of in vivo tumor growth inhibition by RP215 in previous nude mouse experiments. Therefore, heterologous or homologous anti-id antibodies of RP215 that contain the internal image of its specific epitope in CA215 may serve as effective anti-cancer vaccines for therapeutic treatments of various cancers in humans. The relative stability of RP215-specific carbohydrate-associated epitope was compared to that of human IgG at extreme pH's (<or=2 or >or=12) or following NaIO(4) treatments. The major molecular forms of CA215 were further documented with various enzyme immunoassays and found to have similar secondary structures to those of normal human immunoglobulin G.
Lee
Gregory
G
UBC Center for Reproductive Health, The University of British Columbia, Vancouver, BC, Canada. andr@interchange.ubc.ca
Ge
Bixia
B
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000302:isolation & purification / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000302:isolation & purification / Q000494:pharmacology*; D000915:Antibody Affinity; D000951:Antigens, Neoplasm / Q000276:immunology / Q000378:metabolism*; D017209:Apoptosis / Q000187:drug effects; D019496:Cancer Vaccines; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D000939:Epitopes / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D011487:Protein Conformation; D055550:Protein Stability; D011817:Rabbits; D051381:Rats
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; C541379:CA215 antigen, human; D019496:Cancer Vaccines; D000939:Epitopes
Blood. 2001 Aug 15;98(4):1174-81
11493467
Cancer Biol Ther. 2008 Dec;7(12):2007-14
19158477
J Clin Endocrinol Metab. 2008 Aug;93(8):3179-85
18477660
Cancer Res. 2002 Feb 15;62(4):1036-44
11861379
Genes Chromosomes Cancer. 1998 May;22(1):83-6
9591639
World J Gastroenterol. 2007 Apr 28;13(16):2305-11
17511028
Mol Immunol. 2007 Mar;44(9):2221-7
17174398
Cancer Biomark. 2009;5(4):177-88
19729827
Cancer Res. 1995 Dec 1;55(23 Suppl):5978s-5982s
7493380
Cancer Biomark. 2009;5(3):137-42
19407368
FASEB J. 2007 Sep;21(11):2931-8
17475920
Endocr Relat Cancer. 2006 Jun;13(2):641-51
16728589
Cell Signal. 2007 Feb;19(2):419-27
16979873
Oncogene. 2007 May 28;26(25):3594-602
17530013
Cancer Immunol Immunother. 1992;35(1):19-26
1611619
Int J Biochem Cell Biol. 2004 Nov;36(11):2250-7
15313470
Methods Enzymol. 1986;121:652-63
3088385
Nat Rev Cancer. 2008 Feb;8(2):108-20
18219306
Cancer Res. 2003 Oct 1;63(19):6488-95
14559841
Cancer Biol Ther. 2009 Jan;8(2):161-6
19029818
J Reprod Immunol. 2005 Dec;68(1-2):105-20
16303183
J Reprod Immunol. 1988 Aug;13(3):193-209
3262744
Cancer Res. 2006 Apr 15;66(8):3996-4000
16618718
Blood. 1987 Jan;69(1):199-210
2431729
Appl Immunohistochem Mol Morphol. 2008 May;16(3):232-8
18301247